Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
| 0.99 | |
| 0.99 | |
| - | |
| 1.07 | |
| 0.9254 | |
| 0.41-1.1 | |
| 100 M | |
| 102 M | |
| -3 595 000 | |
| -0.05 | |
| 0.195 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Cathie Wood, known for her bold investment strategies through ARK Invest, continues to captivate the financial world with her stock picks. As of 2024, she remains focused on innovative and disruptive ...
If your blue-chip stocks are underperforming, you have a big problem. Blue-chip stocks represent the best, most stable companies and can usually be considered solid performers. There are plenty of goo...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
